Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043878 | 0.81 | HRH3 (0.49) | KDM4EHRH3L3MBTL1CACNA2D1CACNA1B | |
| SCHEMBL23514589 | 0.78 | HRH3 (0.37) | KDM4EHRH3HTR1APOLBNPSR1 | |
| SCHEMBL18713009 | 0.78 | HRH3 (0.37) | KDM4EHRH3HTR1APOLBNPSR1 | |
| SCHEMBL23449305 | 0.78 | PIK3CD (0.48) | KDM4EHRH3PARP1ALDH1A1 | |
| SCHEMBL18713080 | 0.76 | NAMPT (0.45) | KDM4EHRH3POLBNPSR1L3MBTL1 | |
| SCHEMBL27648742 | 0.75 | CACNA2D1 (0.37) | KDM4EHRH3NPSR1CACNA2D1CACNA1B | |
| SCHEMBL19630484 | 0.74 | KDM4E (0.38) | KDM4EPARP1UBE2MDCUN1D1 | |
| SCHEMBL11573468 | 0.74 | — | — | |
| SCHEMBL20349478 | 0.74 | RET (0.33) | KDM4E | |
| SCHEMBL20353644 | 0.74 | HRH3 (0.39) | KDM4EHRH3POLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | KDM4E 1057/4885HRH3 3572/4885HTR1A 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.